2013 Medtech M&A Review: Bayer AG Conceives the Acquisition of Conceptus

Posted in Medical Device Business by MDDI Staff on November 15, 2013

The move expands Bayer's birth control product offerings.

By Clyde A. Burkhardt

Bayer, the $40 billion German giant, substantially enhanced its contraception product portfolio with the acquisition of U.S.-based Conceptus Inc. a developer of minimally invasive devices for reproductive medicine, for $1.1 billion (7.8x sales of $141 million and 39x EBITDA of $28.2 million. With the addition of Conceptus’s Essure nonsurgical, permanent birth-control procedure, Bayer now has a complete range of short- and long-term as well as permanent birth control products. Reportedly, the Essure product has proven to be 99.6% effective in clinical trials.


Clyde A. Burkhardt is senior managing director of HT Capital Advisors LLC (New York City), a private investment banking firm. He leads HT Capital Advisors' groups focusing on the medical device, healthcare services, and precision component industries. Contact Burkhardt at

Printer-friendly version
No votes yet

Login to post comments